Four analysts shared their evaluations of Tango Therapeutics (NASDAQ:TNGX) over the past three months, expressing a mix of bullish and bearish perspectives.
The table below summarizes their recent ratings and illustrates the changing sentiments over the past thirty days and compares them to the previous months.
| Bullish | Somewhat bullish | Indifferent | Somewhat bearish | Bearish | |
|---|---|---|---|---|---|
| Total reviews | 3 | 1 | 0 | 0 | 0 |
| Last 30D | 1 | 0 | 0 | 0 | 0 |
| 1 million ago | 0 | 1 | 0 | 0 | 0 |
| 2M ago | 0 | 0 | 0 | 0 | 0 |
| 3M ago | 2 | 0 | 0 | 0 | 0 |
The analyst-rated 12-month price targets reveal further insights, with an average price target of $15.25, a high estimate of $18.00, and a low estimate of $14.00. With an upside of 47.63%, the current average is up from the previous average price target of $10.33.
Understanding analyst ratings: A comprehensive overview
Tango Therapeutics’ standing among financial experts is revealed through an in-depth exploration of recent analyst actions. The overview below provides an overview of the top analysts, their recent evaluations and adjustments to ratings and price targets.
Key insights:
Navigating these analyst evaluations alongside other financial indicators can contribute to a holistic understanding of Tango Therapeutics’ market position. Stay informed and make data-driven decisions with our assessment table.
Stay up to date with Tango Therapeutics analyst ratings.
If you’re interested in following the news and performance of small cap stocks, you can start here.
Discovering tango therapy: closer
Tangotherapy: a financial overview
Market capitalization: With a limited market capitalization, the company is below the sector average. This reflects a smaller scale compared to industry peers.
Sales growth: Tango Therapeutics’ turnover growth over a period of 3 million is remarkable. As of September 30, 2025, the company achieved revenue growth of approx 363.61%. This indicates a substantial increase in the company’s revenue. Compared to competitors, the company exceeded expectations with a growth rate that was higher than the average for healthcare industry peers.
Net margin: Tango Therapeutics’ net margin exceeds industry standards, underscoring the company’s exceptional financial performance. With an impressive 29.52% net margin, the company manages costs effectively and achieves strong profitability.
Return on Equity (ROE): Tango Therapeutics’ ROE stands out, outperforming industry averages. With an impressive ROE of 10.77%the company demonstrates effective use of equity and strong financial performance.
Return on Assets (ROA): The company’s ROA is performing excellently and exceeding industry averages. With an impressive ROA of 7.09%, the company shows effective use of assets.
Debt management: Tango Therapeutics’ debt-to-equity ratio is below industry norms, indicating a healthy financial structure with a ratio of 0.22.
The Basics of Analyst Ratings
Ratings come from analysts or specialists within the banking and financial systems who report for specific stocks or defined sectors (typically once per quarter for each stock). Analysts typically get their information from company conferences and meetings, financial statements, and conversations with key insiders to make their decisions.
Some analysts publish their forecasts for metrics such as growth estimates, earnings, and revenue to provide additional guidance to their ratings. When using analyst ratings, it is important to keep in mind that stock and sector analysts are human too and only offer their opinions to investors.
This article was generated by Benzinga’s automated content engine and reviewed by an editor.
#Expert #View #Tango #Therapeutics #eyes #analysts #Tango #Therapeutics #NASDAQTNGX